BeOne Medicines Ltd.
BEIGF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001651308
In the last 90 days, BeOne Medicines Ltd. insiders filed 0 open-market purchases and 9 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesONC
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:55 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 25, 2022 |
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Cost of revenue | – | – | – | $286.5M | $164.9M |
| Gross profit | $4.67B | $3.22B | $2.08B | – | – |
| Research and development | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B |
| Selling, general and administrative | $2.08B | $1.83B | $1.50B | $1.28B | $990.1M |
| Operating income | $447.1M | -$568.2M | -$1.21B | -$1.79B | -$1.44B |
| Interest expense | $50.0M | $46.9M | $20.8M | $21.7M | $29.3M |
| Income tax | $129.9M | $111.8M | $55.9M | $42.8M | -$25.2M |
| Net income | $286.9M | -$644.8M | -$881.7M | -$2.00B | -$1.41B |
| EPS, basic | $0.20 | $-0.47 | $-0.65 | $-1.49 | $-1.17 |
| EPS, diluted | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.17 |
| Weighted shares, basic | 1.42B | 1.37B | 1.36B | 1.34B | 1.21B |
| Weighted shares, diluted | 1.47B | 1.37B | 1.36B | 1.34B | 1.21B |
| Margins and growth | |||||
| Gross margin | 87.5% | 84.4% | 84.5% | – | – |
| Operating margin | 8.4% | -14.9% | -49.1% | -126.4% | -122.3% |
| Net margin | 5.4% | -16.9% | -35.9% | -141.5% | -120.2% |
| Revenue growth, year over year | +40.2% | +55.0% | +73.7% | +20.4% | +280.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 25, 2022 |
| Cash and equivalents | $4.55B | $2.63B | $3.17B | $3.87B | $4.38B |
| Short-term investments | – | – | $2.60M | $665.3M | $2.24B |
| Accounts receivable | $865.1M | $676.3M | $358.0M | $173.2M | $483.1M |
| Inventory | $608.2M | $495.0M | $416.1M | $282.3M | $242.6M |
| Total current assets | $6.23B | $3.99B | $4.20B | $5.21B | $7.61B |
| Property, plant and equipment | $1.64B | $1.58B | $1.32B | $845.9M | $587.6M |
| Goodwill | – | – | – | $109.0K | $109.0K |
| Intangible assets | $62.7M | $51.1M | $57.1M | $40.6M | $46.7M |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | $8.65B |
| Accounts payable | $479.0M | $405.0M | $315.1M | $294.8M | $262.4M |
| Short-term debt | $9.06M | $851.5M | $688.4M | $329.0M | $427.6M |
| Total current liabilities | $1.83B | $2.21B | $1.81B | $1.47B | $1.60B |
| Long-term debt | $961.9M | $166.5M | $197.6M | $209.1M | $202.1M |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2.00B | $2.40B |
| Shareholders' equity | $4.36B | $3.33B | $3.54B | $4.38B | $6.24B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 25, 2022 |
| Operating cash flow | $1.13B | -$140.6M | -$1.16B | -$1.50B | -$1.30B |
| Capital expenditures | $185.8M | $492.7M | $561.9M | $325.4M | $262.9M |
| Free cash flow | $941.7M | -$633.3M | -$1.72B | -$1.82B | -$1.56B |
| Depreciation and amortization | $141.7M | $171.8M | $87.7M | $66.3M | $46.5M |
| Stock-based compensation | $510.9M | $441.6M | $367.6M | $303.2M | $240.7M |
| Investing cash flow | -$276.2M | -$548.4M | $60.0M | $1.08B | $640.7M |
| Financing cash flow | $1.06B | $193.4M | $416.5M | -$19.0M | $3.64B |
| Net change in cash | $1.97B | -$547.2M | -$689.1M | -$507.9M | $2.99B |
| Ratio | |||||
| Stock-based compensation, % of revenue | 9.6% | 11.6% | 15.0% | 21.4% | 20.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 1.48B | +3.2% | SEC |
| Jul 31, 2026 | 1.48B | +3.3% | SEC |
| Apr 30, 2026 | 1.45B | +3.0% | SEC |
| Feb 13, 2026 | 1.44B | +4.0% | SEC |
| Nov 1, 2025 | 1.44B | +3.8% | SEC |
| Aug 1, 2025 | 1.43B | +3.7% | SEC |
| May 2, 2025 | 1.40B | +3.2% | SEC |
| Feb 14, 2025 | 1.39B | +2.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.